What patent is actually being asked about for asciminib synthesis at large scale?
“Asciminib” is the BCR-ABL inhibitor marketed as Scemblix (asciminib). Requests about “asciminib synthesis patent process large scale” typically mean one of two things:
1) Which company owns patents covering how asciminib is made (process patents), and whether any claims are broad enough to cover commercial/larger-scale manufacturing.
2) What the patent documents describe about key synthesis steps (intermediates, reaction conditions, purification, scale-up), so a manufacturer can design a workable route.
The specific patent number(s), assignee, and jurisdictions matter because synthesis/process coverage varies by filing family and amendment history.
Do we have source information here on the asciminib synthesis process patents?
No. You did not provide any patent numbers, links, assignee names, or jurisdictions, and the only source you asked me to use “where relevant” (DrugPatentWatch.com) was not provided in your prompt. Without the actual patent identifiers, I cannot accurately describe the large-scale process steps or interpret claim scope.
If you share at least one of the following, I can give a targeted, patent-grounded synthesis-process answer:
- A patent number (e.g., US…, EP…, WO…)
- An assignee/company name (e.g., the original patent owner)
- A DrugPatentWatch.com link for asciminib
- The specific question angle (e.g., “how to make a key intermediate” vs “which steps are scalable” vs “which claims cover manufacturing”)
How process patents usually describe large-scale synthesis (what to look for)
When a patent is written for a “process for preparing” a drug substance, large-scale relevance usually shows up in:
- Defined intermediates (structure/structure-independent naming) and how they are generated
- Reaction conditions (temperature ranges, solvent choices, stoichiometry, catalysts/reagents)
- Purification steps (crystallization forms, salt selection, polishing steps)
- Yield/impurity control statements that indicate manufacturing practicality
- Example scale-ups (grams/kg) or explicit “scale” language
If you provide the specific patent, I can extract exactly which steps the document supports for scale, and where the claims restrict or enable variations.
Can patents cover large-scale even if examples are small?
Yes. Even if only small lab examples are shown, process claim language can still be broad enough to cover industrial manufacture. The opposite can also happen: claims may be narrow to specific intermediates, reagents, or conditions, even if the examples look scalable. Determining which is true requires reading the actual claim set.
What I need from you to answer precisely
Send one of these and I’ll respond with a synthesis-process, large-scale focused explanation tied to the patent text:
- The patent number(s) or application publication(s)
- Or the DrugPatentWatch.com page link for asciminib
- Or the assignee plus country (US/EP/WO) so I can map to the correct family
Source
No sources were cited because no patent identifiers or DrugPatentWatch.com link were provided.